Lou joined Santé Ventures in 2014 and focuses on biotech deal sourcing and management.

Prior to joining Santé, Lou was Partner and Co-Founder at Scale Venture Partners, where he built the firm’s biotechnology practice. He has also held research, project management, business development and sales roles at Gilead Sciences and Genentech.

Lou has played a pivotal role, as an investor and board member, in guiding eight life science companies through successful IPOs, three of which were later acquired for a combined value of more than $70 billion—SeaGen by Pfizer ($43B), Horizon Therapeutics by Amgen ($27B), and Zogenix by UCB ($2B). His portfolio companies have achieved multiple FDA approvals, bringing impactful therapies to patients, including Adcetris for Hodgkin’s lymphoma, Fintepla for Dravet’s Syndrome, Xenazine for Huntington’s disease, and Rayos for rheumatoid arthritis.

Lou currently serves on the board of Santé portfolio company Iterion Therapeutics. He has also held board and investor roles at numerous healthcare companies, including SeaGen, Horizon Therapeutics, Zogenix, Powervision (acquired by Alcon), Prestwick Pharmaceuticals (acquired by Biovail), New Century Hospice (acquired by Curo Health), Orexigen, Somaxon, and SGX Pharmaceuticals. Additionally, he served on the board of SkySong Innovations, the intellectual property management arm of Arizona State University.

Lou earned his MBA in finance from California State University, San Francisco and his BS in biology from California State University, Chico.